Allogene Therapeutics (ALLO) Earnings Date, Estimates & Call Transcripts → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free ALLO Stock Alerts $2.41 -0.03 (-1.23%) (As of 09:34 AM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 7EstimatedActual EPS (May. 13) -$0.38 Beat By $0.03 Consensus EPS (May. 13) -$0.41 Read Call TranscriptListen to Call Get Allogene Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for ALLO and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueALLO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALLO Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad The Freeport SocietyBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________. Allogene Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244($0.58)($0.44)($0.51)Q2 20244($0.58)($0.35)($0.43)Q3 20244($0.59)($0.33)($0.43)Q4 20244($0.59)($0.34)($0.48)FY 202416($2.34)($1.46)($1.84)Q1 20253($0.49)($0.35)($0.41)Q2 20253($0.49)($0.36)($0.42)Q3 20253($0.50)($0.37)($0.43)Q4 20253($0.50)($0.39)($0.45)FY 202512($1.98)($1.47)($1.72)Q1 20261($0.46)($0.46)($0.46)ALLO Earnings Date and InformationAllogene Therapeutics last posted its earnings data on May 13th, 2024. The reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.03. The firm earned $0.02 million during the quarter, compared to analyst estimates of $0.01 million. Its revenue was down 26.7% compared to the same quarter last year. Allogene Therapeutics has generated ($1.79) earnings per share over the last year (($1.79) diluted earnings per share). Earnings for Allogene Therapeutics are expected to decrease in the coming year, from ($1.50) to ($1.59) per share. Allogene Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off prior year's report dates.Read More Allogene Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/7/2024(Estimated)------- 5/13/2024Q1 2024($0.41)($0.38)+$0.03($0.38)$0.01 million$0.02 million 3/14/2024Q4 2023($0.47)($0.43)+$0.04($0.35)$0.05 million$0.02 million11/2/2023Q3 2023($0.53)($0.37)+$0.16($0.37)$0.05 million$0.04 million8/2/2023Q2 2023($0.59)($0.53)+$0.06($0.53)$0.01 million$0.04 million 5/3/2023Q1 2023($0.63)($0.68)($0.05)($0.68)$0.08 million$0.05 million 2/28/2023Q4 2022($0.71)($0.66)+$0.05($0.66)$0.06 million$0.05 million Get the Latest News and Ratings for ALLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/2/2022Q3 2022($0.62)($0.58)+$0.04($0.58)$0.01 million$0.05 million 8/9/2022Q2 2022($0.61)($0.52)+$0.09($0.52)$0.08 million$0.09 million 5/4/2022Q1 2022($0.59)($0.56)+$0.03($0.56)$0.10 million$0.06 million 2/23/2022Q4 2021($0.61)($0.54)+$0.07($0.54)-$0.05 million 11/4/2021Q3 2021($0.56)($0.57)($0.01)($0.57)-$0.05 million 8/3/2021Q2 2021($0.55)($0.53)+$0.02($0.53)$0.95 million$0.04 million 5/4/2021Q1 2021($0.46)($0.25)+$0.21($0.25)$24.50 million$38.35 million 2/24/2021Q4 2020($0.56)($0.53)+$0.03($0.53)-- 11/9/2020Q3 2020($0.54)($0.52)+$0.02($0.52)-- 8/5/2020Q2 2020($0.54)($0.53)+$0.01($0.53)-- 5/6/2020Q1 2020($0.58)($0.58)-($0.50)-- 2/27/2020Q4 2019($0.68)($0.58)+$0.10($0.58)-- 11/5/2019Q3($0.54)($0.50)+$0.04($0.50)-- 8/7/2019Q2 2019($0.47)($0.4131)+$0.0569($0.41)-- Allogene Therapeutics Earnings - Frequently Asked Questions When is Allogene Therapeutics's earnings date? Allogene Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off last year's report dates. Learn more on ALLO's earnings history. Did Allogene Therapeutics beat their earnings estimates last quarter? In the previous quarter, Allogene Therapeutics (NASDAQ:ALLO) reported ($0.38) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.41) by $0.03. Learn more on analysts' earnings estimate vs. ALLO's actual earnings. How can I listen to Allogene Therapeutics's earnings conference call? The conference call for Allogene Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Allogene Therapeutics's conference call transcript? The conference call transcript for Allogene Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Allogene Therapeutics generate each year? Allogene Therapeutics (NASDAQ:ALLO) has a recorded annual revenue of $90,000.00. How much profit does Allogene Therapeutics generate each year? Allogene Therapeutics (NASDAQ:ALLO) has a recorded net income of -$327.27 million. ALLO has generated -$1.79 earnings per share over the last four quarters. What is Allogene Therapeutics's EPS forecast for next year? Allogene Therapeutics's earnings are expected to decrease from ($1.50) per share to ($1.59) per share in the next year. More Earnings Resources from MarketBeat Related Companies: bluebird bio Earnings Results Vir Biotechnology Earnings Results BioCryst Pharmaceuticals Earnings Results Cullinan Therapeutics Earnings Results 4D Molecular Therapeutics Earnings Results Tarsus Pharmaceuticals Earnings Results Ginkgo Bioworks Earnings Results Autolus Therapeutics Earnings Results Immatics Earnings Results Relay Therapeutics Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: CrowdStrike's Earnings: Consolidation and AI-Driven Growth The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyAmerican Superconductor's Earnings Surge, Future Growth ExpectedHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New Heights This page (NASDAQ:ALLO) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.